AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Tolerability/PoP Study in Allergic Rhinitis After Intranasal Administration of AZD8848
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2015-08-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 103
- Registration Number
- NCT00770003
- Locations
- 🇸🇪
Research Site, Lund, Sweden
Symptoms and Management Strategies in Gastroesophageal Reflux Disease (GERD)
Completed
- Conditions
- Gastroesophageal Reflux Disease
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2010-12-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2674
- Registration Number
- NCT00768443
- Locations
- 🇭🇷
Research Site, Zlatar, Croatia
The Performance of Patient Support Program in Early Stage Breast Cancer
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2011-11-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 524
- Registration Number
- NCT00769080
- Locations
- 🇨🇳
Research Site, Hangzhou, Zhejiang, China
A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2012-08-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 38
- Registration Number
- NCT00769119
- Locations
- 🇬🇧
Research Site, New Castle, United Kingdom
Prevalence of EED and Quality of Life Evaluated by Gastroesophageal Reflux Disease (GERD)-Q in Korean GERD Patients
Completed
- Conditions
- Gastroesophageal Reflux Disease
- First Posted Date
- 2008-10-07
- Last Posted Date
- 2010-12-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2000
- Registration Number
- NCT00768196
- Locations
- 🇰🇷
Research Site, Suwon, Kyungkido, Korea, Republic of
To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin
- First Posted Date
- 2008-10-07
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT00768105
- Locations
- 🇺🇸
Research Site, Chula Vista, California, United States
Analysis of Antihypertensive Treatment Efficacy
Terminated
- Conditions
- Arterial Hypertension
- First Posted Date
- 2008-10-07
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2000
- Registration Number
- NCT00767247
- Locations
- 🇷🇺
Research Site, Volgograd, Russian Federation
An Open Label Non-Interventional Evaluation of the Effect of Adjuvant Hormonal Treatment of Postmenopausal Women Wih Early Breast Cancer With Aromatase Inhibitors on Bone Mineral Density and Bone Fracture Rate in Daily Practice
Completed
- Conditions
- Breast CancerOsteoporosis
- First Posted Date
- 2008-10-07
- Last Posted Date
- 2009-07-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 560
- Registration Number
- NCT00767585
- Locations
- 🇸🇮
Research Site, Ljubljana, Slovenia
14729-D9831C00002- 1 Month Biopsy Study
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-10-06
- Last Posted Date
- 2014-02-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 52
- Registration Number
- NCT00766415
- Locations
- 🇬🇧
Research Site, Newcastle upon Tyne, United Kingdom
Investigate the Safety Tolerability and Pharmacokinetics of Multiple Doses of AZD1236
- First Posted Date
- 2008-10-06
- Last Posted Date
- 2009-06-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT00767052
- Locations
- 🇯🇵
Research Site, Osaka-city, Osaka, Japan
© Copyright 2025. All Rights Reserved by MedPath